Companies
Cradle
headquartered in the Netherlands, runs an AI protein-design platform, with its CRADLE-1 model performing automated lead optimization of proteins as a next step beyond de novo generation.
- Country
- Netherlands
EU
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ | ✓ |
| digital-it | — | ✓ | — | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $102.7 million total funding raised, including $73 million Series B in 2024, $24 million Series A in 2023, and $5.7 million seed round in 2022 | cradle.bio · thepharmaletter.com |
| Founded | 2021 | cloud.google.com · thepharmaletter.com |
| Headquarters | Amsterdam, Netherlands | cradle.bio · prnewswire.com · thepharmaletter.com |
| Production site | Wet lab located in Amsterdam, Netherlands | techcrunch.com · cradle.bio · thepharmaletter.com |
| Certification | SOC 2 compliant and ISO 27001 standards; GDPR compliant | similarlabs.com · cradle.bio |
| Regulatory approval | Uses FDA 2025 guidance on computational methods for drug development to support regulatory pathways for AI-designed molecules | synbiointel.com |
Independent sources: cloud.google.com · prnewswire.com · similarlabs.com · synbiointel.com · techcrunch.com · thepharmaletter.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI strain-design & engineering platforms | digital-it | Medium | → |
| Biological AI & bioinformation services | bioinformatics-omics | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.